Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Combinations in Myelofibrosis (ADORE)
NCT04097821Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2019
- Primary completion
- May 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of siremadlin, rineterkib, crizanlizumab, sabatolimab and nisevokitug in myelofibrosis (MF) (8 arms), sponsored by Novartis. Primary endpoints: Incidence and Severity of Dose Limiting Toxicities at Cycle 2 and Response Rate at Cycle 8. Started Sep 2019; status: terminated.
02
Drugs
siremadlinrineterkibcrizanlizumabsabatolimabnisevokitug
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04097821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097821.